Cervicitis – Comprehensive Medical Guide

Overview

Cervicitis is inflammation of the cervix, the lower part of the uterus that protrudes into the upper vagina. Inflammation may be caused by infection, irritation, or an autoimmune response. While cervicitis can affect anyone with a cervix, it is most commonly diagnosed in women of reproductive age (15‑45 years). According to the Centers for Disease Control and Prevention (CDC), about 4‑5 % of sexually active women are diagnosed with cervicitis each year, and the prevalence is higher among those with multiple sexual partners or a history of sexually transmitted infections (STIs).

Most cases are mild and resolve with treatment, but untreated cervicitis can lead to serious reproductive‑health complications, including pelvic inflammatory disease (PID), infertility, and increased risk of acquiring or transmitting HIV.

Symptoms

Symptoms vary from none (asymptomatic) to severe. Common presentations include:

• Abnormal vaginal discharge: watery, mucoid, or purulent (yellow/green) discharge.
• Vaginal bleeding or spotting: especially after intercourse, between periods, or following a pelvic exam.
• Pain or discomfort: burning sensation during urination, dyspareunia (painful intercourse), or lower‑abdominal pain.
• Pelvic pressure: a feeling of heaviness or fullness in the lower abdomen.
• Itching or irritation: around the vaginal opening or cervix.
• Foul odor: often accompanies infectious causes.
• Systemic signs (rare): fever, chills, or malaise may indicate a more severe infection or progression to PID.

Because up to 50 % of women with cervicitis are asymptomatic, routine screening (especially in high‑risk populations) is essential.

Causes and Risk Factors

Infectious Causes

• Sexually transmitted bacteria: Chlamydia trachomatis (most common), Neisseria gonorrhoeae.
• Herpes simplex virus (HSV‑2) – causes ulcerative cervicitis.
• Human papillomavirus (HPV) – especially low‑risk types that cause warts, can irritate the cervix.
• Trichomonas vaginalis – a protozoan parasite.
• Bacterial vaginosis‑associated organisms (e.g., Gardnerella vaginalis).

Non‑Infectious Causes

• Allergic or irritant reactions to contraceptive devices (e.g., diaphragms, spermicides), douches, or soaps.
• Radiation therapy or chemotherapy affecting the pelvic region.
• Autoimmune conditions such as lupus.
• Physical trauma from vigorous sexual activity or foreign bodies.

Risk Factors

• Multiple sexual partners or new sexual relationships.
• History of STIs or PID.
• Inconsistent condom use.
• Use of intrauterine devices (IUDs) that are not properly placed.
• Smoking – impairs local immunity.
• Pregnancy – hormonal changes may increase susceptibility.

Diagnosis

Diagnosis combines a detailed history, physical examination, and targeted laboratory testing.

Clinical Examination

• Pap smear: may incidentally reveal inflammatory cells.
• Speculum exam: visualizes cervical erythema, discharge, or lesions.
• Bimanual exam: assesses for uterine or adnexal tenderness that could suggest PID.

Laboratory Tests

1. Nucleic acid amplification tests (NAATs): the gold standard for detecting Chlamydia and Gonorrhea from cervical swabs (CDC recommendation).
2. Culture or PCR for HSV, Trichomonas, and HPV: ordered if symptoms suggest viral or protozoal infection.
3. Wet mount microscopy: evaluates vaginal secretions for Trichomonas motility, clue cells (BV), or yeast.
4. Blood tests: rarely needed, but may include HIV screening, CBC (if systemic infection suspected), and inflammatory markers.

Imaging (Rare)

If PID is suspected, transvaginal ultrasound may be performed to assess fluid collections or tubo‑ovarian abscesses.

Treatment Options

Treatment is tailored to the identified cause. Empiric therapy is started when testing is pending, especially in high‑risk patients.

Antibiotic Regimens (Bacterial)

• Chlamydia: Doxycycline 100 mg orally twice daily for 7 days (CDC 2021). Alternative: Azithromycin 1 g single dose.
• Gonorrhea: Ceftriaxone 500 mg IM (or 1 g if >150 kg) plus Azithromycin 1 g PO single dose (dual therapy to address potential co‑infection).
• Trichomoniasis: Metronidazole 2 g PO single dose or 500 mg BID for 7 days.
• Bacterial vaginosis (if contributory): Metronidazole 500 mg PO BID for 7 days.

Antiviral Therapy (Viral)

• Herpes simplex virus: Acyclovir 400 mg PO three times daily for 7‑10 days, or valacyclovir 500 mg PO twice daily.
• HPV: No antiviral; management focuses on lesion removal (cryotherapy, LEEP) and monitoring.

Procedural Interventions

• Cervical biopsies: performed if suspicious lesions are present to rule out dysplasia or cancer.
• LLETZ/LEEP: loop electrosurgical excision for high‑grade lesions.

Lifestyle & Supportive Care

• Complete the full course of prescribed medication—even if symptoms improve.
• Avoid intravaginal douches, scented soaps, and irritants during treatment.
• Use condoms consistently to reduce reinfection risk.
• Partner notification and treatment are essential; untreated partners are a common source of recurrence.

Living with Cervicitis

While most episodes resolve, some women experience recurrent inflammation. Practical tips include:

• Regular follow‑up: Re‑test for Chlamydia/Gonorrhea 3 months after treatment, per CDC guidelines.
• Maintain a healthy vaginal microbiome: Probiotic‑rich foods (yogurt, kefir) and, if appropriate, lactobacillus suppositories.
• Stress management: Chronic stress can impair immune response; techniques such as mindfulness or yoga are beneficial.
• Safe-sex practices: Limit the number of sexual partners, use barrier methods, and discuss STI testing with partners.
• Pelvic floor exercises: Strengthening muscles can reduce pelvic discomfort associated with chronic inflammation.

Prevention

1. Vaccination: HPV vaccine (Gardasil 9) protects against strains that cause cervical warts and dysplasia.
2. Routine STI screening: Annual testing for sexually active women under 25, and for older women with risk factors (CDC).
3. Condom use: Consistent latex or polyurethane condom use reduces transmission of bacterial and viral pathogens.
4. Avoid vaginal irritants: Skip scented tampons, sprays, and douches.
5. Proper IUD care: Ensure correct placement and routine check‑ups.
6. Smoking cessation: Improves local immunity and overall reproductive health.

Complications

If left untreated, cervicitis can progress to more serious conditions:

• Pelvic inflammatory disease (PID): Infection ascends to the uterus, fallopian tubes, and adjacent structures. PID occurs in ~10‑20 % of untreated Chlamydia infections (CDC).
• Infertility: Scarring of the fallopian tubes from PID can impair conception.
• Ectopic pregnancy: Damaged tubes increase the risk of implantation outside the uterus.
• Chronic pelvic pain: Persistent inflammation may cause lasting discomfort.
• Increased HIV acquisition/transmission: Inflamed cervical tissue is more susceptible to viral entry.
• Cervical dysplasia or cancer: Chronic HPV infection combined with inflammation can accelerate neoplastic changes.

When to Seek Emergency Care

References

• Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines, 2021.
• Mayo Clinic. “Cervicitis.” Updated 2023.
• World Health Organization. “WHO Guidelines for the Treatment of Chlamydia trachomatis.” 2022.
• Cleveland Clinic. “Pelvic Inflammatory Disease.” Accessed 2024.
• National Institutes of Health. “Human Papillomavirus (HPV) Vaccination.” 2024.
• American College of Obstetricians and Gynecologists. “Screening for Cervical Cancer.” Committee Opinion No. 856, 2023.